These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37607622)

  • 1. Reply to: "Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations".
    Petermann-Rocha F; Ho FK; Pell JP
    J Hepatol; 2023 Dec; 79(6):e233-e234. PubMed ID: 37607622
    [No Abstract]   [Full Text] [Related]  

  • 2. Defining severe NAFLD based on ICD codes in large cohorts: Balancing feasibility and limitations.
    Long L; Zhou X
    J Hepatol; 2023 Dec; 79(6):e232-e233. PubMed ID: 37160166
    [No Abstract]   [Full Text] [Related]  

  • 3. Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM.
    Hayward KL; Johnson AL; Horsfall LU; Moser C; Valery PC; Powell EE
    BMJ Open Gastroenterol; 2021 Feb; 8(1):. PubMed ID: 33568418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Administrative coding for non-alcoholic fatty liver disease is accurate in Swedish patients.
    Åström H; Wester A; Hagström H
    Scand J Gastroenterol; 2023; 58(8):931-936. PubMed ID: 36890670
    [No Abstract]   [Full Text] [Related]  

  • 5. Periodontal disease could be a potential risk factor for non-alcoholic fatty liver disease: An 11-year retrospective follow-up study.
    Shin HS; Hong MH; Moon JY; Sim SJ
    Clin Oral Investig; 2022 Aug; 26(8):5503-5514. PubMed ID: 35556175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonalcoholic fatty liver disease is specifically related to the risk of hepatocellular cancer but not extrahepatic malignancies.
    Albhaisi S; McClish D; Kang L; Gal T; Sanyal AJ
    Front Endocrinol (Lausanne); 2022; 13():1037211. PubMed ID: 36506048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population.
    Sayiner M; Arshad T; Golabi P; Paik J; Farhat F; Younossi ZM
    Hepatol Int; 2020 Jul; 14(4):556-566. PubMed ID: 32300995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
    Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
    Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.
    Musso G; Gambino R; Tabibian JH; Ekstedt M; Kechagias S; Hamaguchi M; Hultcrantz R; Hagström H; Yoon SK; Charatcharoenwitthaya P; George J; Barrera F; Hafliðadóttir S; Björnsson ES; Armstrong MJ; Hopkins LJ; Gao X; Francque S; Verrijken A; Yilmaz Y; Lindor KD; Charlton M; Haring R; Lerch MM; Rettig R; Völzke H; Ryu S; Li G; Wong LL; Machado M; Cortez-Pinto H; Yasui K; Cassader M
    PLoS Med; 2014 Jul; 11(7):e1001680. PubMed ID: 25050550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Cardiovascular Risk Factors and Metabolic Syndrome with non-alcoholic and alcoholic fatty liver disease: a retrospective analysis.
    Han AL
    BMC Endocr Disord; 2021 May; 21(1):91. PubMed ID: 33933056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
    Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
    Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
    Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
    J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network.
    Namjou B; Lingren T; Huang Y; Parameswaran S; Cobb BL; Stanaway IB; Connolly JJ; Mentch FD; Benoit B; Niu X; Wei WQ; Carroll RJ; Pacheco JA; Harley ITW; Divanovic S; Carrell DS; Larson EB; Carey DJ; Verma S; Ritchie MD; Gharavi AG; Murphy S; Williams MS; Crosslin DR; Jarvik GP; Kullo IJ; Hakonarson H; Li R; ; Xanthakos SA; Harley JB
    BMC Med; 2019 Jul; 17(1):135. PubMed ID: 31311600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Frequency of diagnosed non-alcololic fatty liver disease (NAFLD) in the German population - An analysis based on health insurance data].
    Stahmeyer JT; Hemmerling M; Burger B; Eberhard S; Krauth C; Zeidler J; Herr A; Weseloh H; Rossol S
    Z Gastroenterol; 2021 Aug; 59(8):851-858. PubMed ID: 33757144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease is not a causal risk factor for psoriasis: A Mendelian randomization study of 108,835 individuals.
    Näslund-Koch C; Bojesen SE; Gluud LL; Skov L; Vedel-Krogh S
    Front Immunol; 2022; 13():1022460. PubMed ID: 36353626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between non-alcoholic fatty liver disease and the risk of dementia: A nationwide cohort study.
    Kim GA; Oh CH; Kim JW; Jeong SJ; Oh IH; Lee JS; Park KC; Shim JJ
    Liver Int; 2022 May; 42(5):1027-1036. PubMed ID: 35289469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus infection and the risk of liver disease progression in type 2 diabetic patients with potential nonalcoholic fatty liver disease: a retrospective, observational, cohort study in the United Kingdom Clinical Practice Research Datalink.
    Ferreira G; Stuurman AL; Horsmans Y; Cattaert T; Verstraeten T; Feng Y; Rosillon D; Guignard A
    Eur J Gastroenterol Hepatol; 2020 Jan; 32(1):101-109. PubMed ID: 31651649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Nonalcoholic Fatty Liver Disease in Children: 2009-2018.
    Sahota AK; Shapiro WL; Newton KP; Kim ST; Chung J; Schwimmer JB
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 33214329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.